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Abstract
Background While in vitro and animal studies have shown
reduced cytochrome P450 (CYP) 3A activity due to obesity,
clinical studies in (morbidly) obese patients are scarce. As
CYP3A activity may influence both clearance and oral bio-
availability in a distinct manner, in this study the pharmacoki-
netics of the CYP3A substrate midazolam were evaluated after
semi-simultaneous oral and intravenous administration in
morbidly obese patients, and compared with healthy volunteers.
Methods Twenty morbidly obese patients [mean body
weight 144 kg (range 112–186 kg) and mean body mass
index 47 kg/m2 (range 40–68 kg/m2)] participated in the
study. All patients received a midazolam 7.5 mg oral and
5 mg intravenous dose (separated by 159 ± 67 min) and
per patient 22 samples over 11 h were collected. Data from
12 healthy volunteers were available for a population
pharmacokinetic analysis using NONMEM.
Results In the three-compartment model in which oral
absorption was characterized by a transit absorption model,
population mean clearance (relative standard error %) was
similar [0.36 (4 %) L/min], while oral bioavailability was
60 % (13 %) in morbidly obese patients versus 28 % (7 %)
in healthy volunteers (P \ 0.001). Central and peripheral
volumes of distribution increased substantially with body
weight (both P \ 0.001) and absorption rate (transit rate
constant) was lower in morbidly obese patients [0.057
(5 %) vs. 0.130 (14 %) min–1, P \ 0.001].
Conclusions In morbidly obese patients, systemic clear-
ance of midazolam is unchanged, while oral bioavailability
is increased. Given the large increase in volumes of dis-
tribution, dose adaptations for intravenous midazolam
should be considered. Further research should elucidate the
exact physiological changes at intestinal and hepatic level
contributing to these findings.
Key Points
No influence of obesity on the systemic clearance of
the cytochrome P450 3A substrate midazolam could
be identified when morbidly obese and non-obese
subjects were studied.
Midazolam oral bioavailability is increased in
morbidly obese individuals.
Midazolam volume of distribution increases
substantially with body weight, necessitating dose
adaptations for intravenous midazolam in morbidly
obese patients.
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1 Introduction
The prevalence of obesity [body mass index (BMI)
[30 kg/m2] and morbid obesity (BMI [40 kg/m2) is
increasing rapidly. In 2010, 6.6 % (15.5 million) of the US
adult population was morbidly obese, a 70 % increase
since 2000 [1], while 36 % of the US population was obese
[2]. In Europe, approximately 20 % of the adult population
is currently obese [3].
In obese mice, studies have shown reduced hepatic
cytochrome P450 (CYP) 3A protein expression [4, 5].
Similarly, in in vitro studies with hepatocytes from human
fatty livers, reduced CYP3A expression and activity has
been reported [6, 7] with increasing severity of fatty liver
and non-alcoholic steatohepatitis (NASH), which are both
highly associated with (morbid) obesity [8, 9]. However,
these measurements concern absolute values and were not
normalized for the weight of the whole liver and/or the
body weight of the mouse. CYP3A is an important enzyme
system that is responsible for the primary metabolism of
25 % of all clinically used drugs [10], including many
drugs that are relevant for obese patients, such as statins
(HMG-CoA reductase inhibitors), cardiovascular drugs,
antipsychotics, and oncolytic drugs [11]. In obese com-
pared with non-obese subjects, it was shown that hepatic
and intestinal CYP3A protein expression decreased with
increasing BMI [12] and that oral clearance (CL/F) of
CYP3A substrates such as triazolam, carbamazepine, and
taranabant was lower [13, 14], even though a similar sys-
temic clearance (CL) was found in obese individuals for
midazolam [15]. An explanation for the reduction in
CYP3A activity upon obesity could be an increased state of
inflammation caused by infiltration of macrophages and
adipocytes into the adipose tissue excreting inflammation
markers and adipokines, such as interleukin (IL)-6 and
tumor necrosis factor (TNF)-a [16–18]. Both in vitro and
animal studies have shown that inflammation factors such
as IL-6 may decrease CYP3A expression, resulting in
down-regulation of CYP3A-mediated metabolism [19–23].
Finally, reduced CYP3A activity due to inflammation has
also been shown in critically ill patients [24, 25].
Midazolam, which is considered a specific marker of
CYP3A activity because it is primarily metabolized by
CYP3A [26], is a widely applied oral or intravenous drug
for sleeping disorders, (pre)anesthesia, sedation for scopic
interventions, and in the intensive care unit. As CYP3A is
located in both the liver and the intestines, the activity of
the CYP3A enzyme is an important determinant of
midazolam CL and oral bioavailability [27, 28]. In view of
the ever-increasing body weights of morbidly obese
patients, in this pharmacokinetic study we evaluate the
influence of morbid obesity on CYP3A-mediated CL and
oral bioavailability of midazolam when studied after semi-
simultaneous oral and intravenous administration, allowing
these parameters to be characterized in a distinct manner.
For the analysis, midazolam data from a healthy volunteer
study with the same study design were also available. The
results of this study are used to illustrate the consequences
for dosing of oral and intravenous midazolam in morbidly
obese patients.
2 Methods
2.1 Study Design and Patients
This prospective observational study in morbidly obese
patients (NTC01519726 and EudraCT 2011-003293-93)
was approved by the local human research and ethics
committee of the Sint Antonius Ziekenhuis (VCMO,
NL35861.100.11) and conducted in accordance with the
principles of the Declaration of Helsinki and the Medical
Research Involving Human Subjects Act (WMO) of The
Netherlands. Before participation, all patients gave written
informed consent.
Adult morbidly obese patients (BMI [40 kg/m2)
undergoing laparoscopic gastric bypass or sleeve surgery
were eligible for inclusion in the study. Patients were
excluded if they used CYP3A-inducing or -inhibiting
medication according to the Cytochrome P450 Drug
Interaction Table [11], used products containing grapefruit,
wild grape, banpeiyu, pomegranate, star fruit, or black
berry within 2 weeks before the study, were pregnant or
breastfeeding, or suffered from renal insufficiency (esti-
mated glomerular filtration rate [Modification of Diet in
Renal Disease (MDRD4) \60 mL/min].
2.2 Study Procedure
Twenty morbidly obese patients were studied on the day of
laparoscopic bariatric surgery after an overnight fast.
Midazolam was administered in a semi-simultaneous
manner. Approximately 2.5 h before induction of anes-
thesia, patients received midazolam 7.5 mg orally as a
tablet (Dormicum, Roche). At the induction of anesthesia
(159 ± 67 min after the oral dose), 5 mg of intravenous
midazolam (Midazolam Actavis 5 mg/mL, Actavis) was
administered. Blood samples were collected at T = 0, 5,
15, 30, 45, 55, 65, 75, 90, 120, and 150 min after the oral
dose and T = 5, 15, 30, 30, 90, 120, 150, 180, 210, 270,
330, 390, and 510 min after the intravenous dose. Blood
samples were collected in lithium heparin tubes and cen-
trifuged at 3,000 rpm for 10 min at 4 C. Plasma was
separated and immediately stored at -80 C until analysis.
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Blood samples to measure markers of liver function
[aspartate aminotransferase (AST), alanine aminotransfer-
ase (ALT), bilirubin, c-glutamyltransferase, and albumin]
in morbidly obese patients were collected before the oral
midazolam dose was administered.
2.3 Control Group
Data from 12 healthy volunteers receiving midazolam in an
identical semi-simultaneous dosing design were available
for analysis (EudraCT 2009-010331-40). Subjects had to
fast from 2 h before drug administration and received a
2 mg oral midazolam solution (Midazolam, Synthon) at
10:00 am. After 150 min they received a 1 mg intravenous
midazolam dose (Midazolam, Synthon) and blood samples
were collected at T = 15, 30, 45, 60, 65, 70, 75, 80, 90,
120, 148, 155, 165, 180, 210, 240, 270, 330, and 390 min
after oral dose.
2.4 Drug Assay
In the plasma samples from morbidly obese patients,
midazolam was analyzed using a MassTox TDM series A
BASIC-Kit for ultra performance liquid chromatography
(UPLC)–tandem mass spectrometry (MS/MS) from
Chromsystems Instruments and Chemicals GmbH (Gra¨-
felfing/Mu¨nchen, Germany), a commercially available kit
including mobile phases, dilution buffers, and extraction
buffer. For sample preparation, 25 lL of MassTox
BASIC-Kit A extraction buffer was added to 50 lL of the
sample. After short vortex mixing, this mixture was let to
incubate for 2 min. Then 250 lL MassTox BASIC-Kit A
internal standard mix was added and the mixture was
vortexed for 30 s and centrifuged at 15,000 g for 5 min.
Ten lL of the supernatant was injected onto the UPLC
column (MasterColumn, Chromsystems) without a pre-
column using a Waters Acquity UPLC system connected to
a Waters TQD (TQ Detector) mass spectrometer with
electrospray ionization. The column was kept at 25 C.
Eluent was used at a flow rate of 0.6 mL/min. Intra-assay
and inter-assay coefficients of variation were 4.7 and
3.3 %, respectively. Midazolam recovery was 90 %. The
lower limit of quantification (LLOQ) was 0.8 ng/mL.
In the plasma samples from healthy volunteers, midaz-
olam was measured using a validated liquid chromato-
graphic–tandem mass spectrometric (LC-MS/MS) assay.
Briefly, 500 lL acetonitrile containing midazolam-D4
(4 lg/L) was added to 200 lL serum. After 3 min vortex
mixing and 5 min centrifugation at ambient temperature
the supernatant was collected and transferred into an
autosampler vial. Next, 10 lL was injected on an Atlantis
T3 C18 3 lm column (2.1 9 50 mm; Waters), protected
with a guard column (ODS; 4 9 3 mm), which was kept at
30 C. Gradient elution was performed with a mobile phase
consisting of 0.1 % v/v aqueous formic acid and 0.1 % v/v
formic acid in acetonitrile at a flow rate of 0.3 mL/min.
The effluent was monitored with a Micromass Quattro
Micro triple-quadrupole mass spectrometric detector
(Waters). The detector was operated in the positive elec-
trospray ionization mode and configured in the multiple
reaction monitoring (MRM) mode. Within-day and
between-day inaccuracy and imprecision were less than
5 %. The LLOQ was 0.3 ng/mL.
2.5 Population Pharmacokinetic Analysis and Internal
Validation
Population pharmacokinetic modeling was performed on
all data by means of non-linear mixed-effects modelling
using NONMEM (version 7.2; GloboMax LLC, Hanover,
MD, USA) [29]. Pirana (2.7.1; Pirana Software & Con-
sulting BV) and R (2.15) were used to visualize the data.
All midazolam plasma concentration values that were
received from the laboratory were inserted in the datafile,
even if these were below the limit of quantification (LOQ).
Of the 434 samples from morbidly obese patients, 42 were
below the LOQ. For healthy volunteers, no data were
below the LOQ.
Discrimination between different models was made by
comparison of the objective function value (OFV; i.e., -2
log likelihood [-2LL]). A P value below 0.05, represent-
ing a decrease of 3.84 in the OFV for one degree of free-
dom, was considered statistically significant. In addition,
goodness-of-fit plots (observed versus individual-predicted
concentrations, observed versus population-predicted con-
centrations, conditional weighted residuals versus time,
and conditional weighted residuals versus population-pre-
dicted concentrations plots) were used for diagnostic pur-
poses. Furthermore, the confidence interval of the
parameter estimates, the correlation matrix, and visual
improvement of the individual plots were used to evaluate
the model. The internal validity of the population phar-
macokinetic model was assessed by the bootstrap re-sam-
pling method using 500 replicates and normalized
prediction distribution errors (NPDE) using 1,000 simula-
tion of each dataset [30]. Parameters obtained with the
bootstrap replicates were compared with the estimates
obtained from the original dataset. NPDE plots were
checked for normal distribution characteristics and trends
in the data errors [30].
For the structural model, one-, two, and three-compart-
ment models with an oral dosing compartment were tested.
To describe the midazolam oral absorption phase, zero-
order and first-order absorption models were tested, in
addition to a lag time model and a transit absorption model
[31]. For the transit absorption model, a varying number of
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transit compartments was tested. As the transit rate (Ktr)
was set equal to the absorption rate (Ka), the mean tran-
sit time (MTT) can be calculated from Ktr with
1/(Ktr*(n ? 1)), in which n is the number of transit com-
partments [32].
For the statistical model, the individual parameter esti-
mate (empirical Bayes estimate or post hoc value) of the ith
individual was modelled according to (Eq. 1):
hi ¼ hmean  egi ð1Þ
where hmean is the population mean and gi is a random
variable for the ith individual with a mean of zero and
variance of x2, assuming log-normal distribution in the
population.
For residual variability, resulting from assay errors,
model misspecifications, and other unexplained sources, a
proportional error model and a combined proportional and
additive model was tested for each of the datasets. The jth
observed midazolam concentration of the ith healthy vol-
unteer (Yij) is described by Eq. 2, while the jth observed
midazolam concentration of the ith morbidly obese patient
(Yij) is described by Eq. 3:
Yij ¼ Cpred;ij  ð1 þ eijÞ ð2Þ
Yij ¼ Cpred;ij  ð1 þ eijÞ þ eij ð3Þ
where Cpred,ij is the population-predicted midazolam con-
centration of the ith individual at the jth time, and eij is a
random variable with a mean of zero and variance of r2.
2.6 Covariate Analysis
Covariates were plotted independently against the indi-
vidual post hoc values and eta estimates of pharmacoki-
netic parameters to visualize potential relations. The
following covariates were tested: total body weight (TBW),
BMI, lean body weight (LBW) [33], sex, morbid obesity
and age. All covariates except for sex and morbid obesity
were tested using linear and allometric equations (Eqs. 4
and 5):
Pi ¼ Pp  ð1 þ W  ðCOVi  COVmedianÞ ð4Þ




where Pi and Pp represent individual and population
parameter estimates, respectively; COV represents the
covariate; COVmedian represents the median value of the
covariate for the population; W represents a correlation
factor between the population pharmacokinetic parameters
and the change in covariate value; and X represents the
exponential scaling factor for a power function. The binary
covariates ‘sex’ and ‘morbid obesity’ were tested using
Eq. 6:
Pi ¼ Pp  ZCOV ð6Þ
where Pi and Pp represent the individual and population
parameter estimate, and Z represents the estimated factor of
increase or decrease for the patients subgroup with COV
equalling 1.
Potential covariates were separately entered into the
model and statistically tested by use of the OFV and, if
applicable, the 95 % confidence interval of the additional
parameter. In addition, if applicable, it was evaluated
whether the inter-individual variability (eta) in the
parameter concerned decreased upon inclusion of the
covariate on the parameter and whether the trend in the eta
versus covariate plot had resolved. When more than one
significant covariate for the simple model was found, the
covariate-adjusted model with the largest decrease in the
OFV was chosen as a basis to sequentially explore the
influence of additional covariates with the use of the same
criteria. Finally, after forward inclusion (P \ 0.05), a
backward exclusion procedure was applied to justify the
inclusion of a covariate (P \ 0.01). The choice of the
covariate model was further evaluated as discussed in the
Population Pharmacokinetic Analysis and Internal Valida-
tion section.
2.7 Model Simulations
Using NONMEM 7.2, the final population pharmacoki-
netic model was used to simulate the concentration–time
profiles of four typical patients from the dataset, including
one healthy volunteer of 76 kg and three morbidly obese
patients of 112, 145, and 186 kg. The 76 and 145 kg dose
simulations represent the median body weight of the
healthy volunteer and morbidly obese patient group,
respectively. In addition, the 112 and 186 kg dose simu-
lations represent the extremes of the body weight range of
the morbidly obese patient group (see Table 1).
3 Results
3.1 Patients and Data
Twenty morbidly obese patients participated in this study
and a mean of 22 ± 3 samples per patient were available
for analysis. In addition, data from 12 healthy volunteers
with 19 midazolam concentrations per subject were used as
a control group in this analysis.
Liver function markers in morbidly obese subjects were
all within three times the upper limit of normal, with the
vast majority being within two times the upper limit of
normal of the different markers. The demographics of all
subjects are summarized in Table 1.
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3.2 Population Pharmacokinetic Model and Validation
A three-compartment model with two equalized peripheral
volumes of distribution best fitted the data. This model
showed an improved fit over a two-compartment model,
while a full three-compartment model could not be esti-
mated with adequate precision. The pharmacokinetic
model was parameterized in terms of oral Ka, oral bio-
availability, volume of distribution of the central com-
partment (V1), two equalized volumes of distribution of the
peripheral compartments (V2 and V3), inter-compartmental
clearances from the central compartment to each peripheral
compartment (Q and Q2), and clearance from the central
compartment (CL). Midazolam oral absorption described
by three transit absorption compartments proved superior
over the other oral absorption models (zero and/or first-
order absorption models or a lag time model) (Fig. 1). An
omega block was implemented to account for the correla-
tion between the central and peripheral volume of distri-
bution. Table 2 shows the parameter estimates of the
simple model without covariates.
In the covariate analysis, a significant influence of TBW
or ‘morbid obesity’ was found on four different parameters,
which is visualized in Fig. 2 where the post hoc parameters
of the simple model without covariates are given. It was
found that the peripheral volumes of distribution increased
in a non-linear manner with TBW (P \ 0.001, -24
DOFV), and that the central volume of distribution showed
a linear increase with body weight (P \ 0.001, -17
DOFV). For oral bioavailability and Ka (or Ktr), ‘morbid
obesity’ was a significant covariate and significantly
improved the model (P \ 0.001, -22 DOFV and
P \ 0.001, -20 DOFV, respectively). For clearance, there
was a trend towards a positive influence of LBW but not
for TBW; however, the statistical significance was insuf-
ficient for inclusion of LBW in the final covariate model
(P \ 0.05, -4 DOFV), the estimated correlation factor was
not estimated with adequate precision, and the eta for
clearance value was not reduced. Eta distributions for
clearance versus body weight and LBW of the simple and
final covariate model are included in the Electronic Sup-
plementary Material (ESM 1). After inclusion of the
covariates in the model, the trends in eta value of the
parameter and the covariate had disappeared and no
residual trends were observed (Electronic Supplementary
Material, ESM 2). All parameter estimates of the final
model are shown in Table 2. Figure 3 demonstrates the
goodness-of-fit plots of the final covariate model. The plots
show no remaining bias for predicted midazolam concen-
trations in morbidly obese patients or healthy volunteers.
The final model was internally validated by means of 500
bootstrap runs (Table 2), which were successful in 96 % of
the runs and confirmed the parameter values. Finally, an
NPDE analysis was performed showing a normal
Table 1 Characteristics of 20 morbidly obese patients and 12 healthy volunteers
Variable Morbidly obese patients (n = 20) Healthy volunteers (n = 12) P value
Female/male (n) 12/8 0/12
Age (years) 43.6 ± 7.6 (26–57) 22.0 ± 3.1 (18–27) \0.001
Body weight (kg) 144.4 ± 21.7 (112–186) 76.0 ± 8.7 (63–93) \0.001
Lean body weight (kg) [33] 71.5 ± 11.9 (53–95) 61.2 ± 5.0 (53–70) \0.005
Body mass index (kg/m2) 47.1 ± 6.5 (40–68) 22.3 ± 2.4 (19–26) \0.001
Number of samples per patient 21.7 ± 2.7 (13–24) 19 ± 0.0 (19–19) \0.001
Samples below the limit of quantification (%) 9.7 0 –
Values are expressed as mean ± standard deviation (range) unless specified otherwise
Fig. 1 Schematic illustration of the population pharmacokinetic
model of oral and intravenous administered midazolam. CL clearance,
F oral bioavailability, i.v. intravenous, Ka oral absorption rate, Ktr
transit rate constant, mdz midazolam, Q inter-compartmental clear-
ance to first peripheral volume, Q2 inter-compartmental clearance to
second peripheral volume, V volume of distribution
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distribution of errors without trends, except for the initial
midazolam concentrations in morbidly obese patients,
which were below the LOQ (see Electronic Supplementary
Material, ESM 3). The NONMEM control file of the final
model is provided as a Electronic Supplementary Material
(ESM 4)
3.3 Simulations
Figure 4 shows population predicted midazolam concen-
trations after a 5 mg intravenous bolus dose, a 2.5 mg/h
continuous infusion for a duration of 10 days (14,400 min),
and a 7.5 mg oral dose in four typical subjects from the
dataset (i.e., 76, 112, 145, and 186 kg). The plot shows that
for the intravenous bolus dose, midazolam maximum
(peak) concentrations (Cmax) are lower in morbidly obese
patients (Fig. 4a), which may be the result of the higher
central volume of distribution in morbidly obese patients.
In addition, the plot illustrates the longer midazolam
elimination half-life (t) in morbidly obese patients, which
can be attributed to the increase in volumes of distribution
with body weight, while clearance is the same in all
patients. The continuous intravenous infusion simulation
(Fig. 4b) shows that with increasing body weight the
Table 2 Population pharmacokinetic parameters of the simple and final pharmacokinetic model for midazolam in 20 morbidly obese patients
and 12 healthy volunteers and results from a bootstrap analysis of the final model (479/500 re-samples successful)
Parameter Simple model (RSE%) Final model (RSE%) Bootstrap (SE)
Fixed effects
CL (L/min) 0.36 (4.9) 0.359 (4.4) 0.358 (0.016)
F 0.414 (12.8) –
F morbidly obese – 0.603 (13.2) 0.603 (0.081)
F healthy volunteers – 0.284 (7.0) 0.286 (0.020)
Ka (min-1) = Ktr 0.086 (3.4)a –
Ka = Ktr morbidly obese – 0.057 (13.6)b 0.058 (0.059)
Ka = Ktr healthy volunteers – 0.13 (5.1)b 0.130 (0.006)
Vcentral (L) 36.4 (7.8) –
Vcentral = V127 kg 9 (1 ? Z 9 (TBW – 127))
Vcentral, 127 kg – 44.1 (16.1) 43.6 (6.9)
Z – 0.0105 (15.8) 0.0102 (0.002)
Vmidazolam peripheral (L) 76.6 (8.4) –
Vperipheral = V127 kg 9 (TBW/127)
W
Vperipheral, 127 kg – 139 (15.2) 138.7 (22.9)
W – 3.06 (8.2) 3.07 (0.28)
Q (L/min) 1.31 (12.8) 1.33 (11.8) 1.33 (0.143)
Q2 (L/min) 0.153 (12.1) 0.15 (14.6) 0.15 (0.023)
Interindividual variability (%)
CL 19.7 (32.6) 18.1 (30.7) 17.2 (14.6)
F 61.2 (20.8) 26.4 (17.4) 25.4 (14.6)
Ka = Ktr 50.7(10.9) 41.4 (12.8) 39.9 (18.4)
Vcentral 102.8 (13.2) 55.2 (17.5) 53.5 (30.8)
Vperipheral 152.3 (13.9) 34.4 (26.5) 33.6 (23.7)
Correlation between eta Vcentral and Vperipheral 0.783 (50.0) 0.12 (24.5) 0.10 (0.058)
Residual variability (%)
Proportional error healthy volunteers 10.0 (21.5) 10.0 (21.3) 9.9 (4.4)
Proportional error morbidly obese patients 31.0 (17.1) 46.7 (11.6) 46.6 (15.6)
Additive error morbidly obese patients 3.1 (37.3)
OFV 4,077 4,003 3,982 (145)
CL systemic clearance of midazolam, F oral bioavailability, Ka oral absorption rate, Ktr transit compartment rate, Q inter-compartmental
clearance of midazolam between the central and first peripheral compartment, Q2 inter-compartmental clearance of midazolam between the
central and second peripheral compartment, OFV objective function value, RSE relative standard error, SE standard error, TBW total body
weight, V volume of distribution
a Mean transit time is 46.5 min
b Mean transit times are 70.2 and 30.8 min, respectively
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midazolam steady-state concentrations are reached at a
later timepoint. In a 76 kg healthy volunteer, steady state is
expected to be reached after 24 h, while this is 170 h in a
145 kg morbidly obese patient and [240 h in a 186 kg
morbidly obese patient (Fig. 4b). Finally, the oral midaz-
olam dose simulations (Fig. 4c) show that the time to reach
the Cmax is later (31 min) in morbidly obese patients than
in healthy volunteers, while the Cmax is slightly lower in
morbidly obese patients.
4 Discussion
As there is only limited information on the influence of
morbid obesity on CYP3A-mediated clearance of drugs in
patients, this study aimed to evaluate the pharmacoki-
netics of the CYP3A substrate midazolam in morbidly
obese patients following oral and intravenous adminis-
tration. As clearance after oral dosing is dependent on
oral bioavailability, which may be influenced by CYP3A
enzyme activity in the intestines, this semi-simultaneous
design allows for an estimation of both CL and oral
bioavailability in a distinct manner. An available dataset
of midazolam concentrations collected on the basis of an
equivalent study design in healthy volunteers allowed for
a head-to-head comparison between morbidly obese
patients and non-obese healthy subjects. The results from
this study show that midazolam clearance was similar in
morbidly obese patients and healthy volunteers, oral
bioavailability was substantially higher (60 % instead of
28 %), oral Ka was reduced, and that the central and
peripheral volumes of distribution increased substantially
with body weight. Particularly for intravenous dosing, the
net results of all these changes should be considered
when administering midazolam to morbidly obese
patients.
In this study, we could not identify an influence of
morbid obesity on the CL of midazolam, even though a
wide range in body weights was included in this study. We
did find a trend of increasing midazolam clearance with
LBW; however, this trend was not strong enough for
inclusion in the final covariate model. Possibly, the patient
numbers in this analysis (n = 12 ? n = 20) are insuffi-
cient to adequately detect a small increase in clearance
with LBW. While these results indicate a lack of change in
absolute hepatic CYP3A-mediated metabolism of midaz-
olam in morbidly obese individuals, the results are in
contrast with our expectations of a lower midazolam













































































Fig. 2 Post hoc parameter
estimates of morbidly obese
individuals (n = 20, black dots)
and healthy individuals
(n = 12, gray dots) from the
simple pharmacokinetic model
versus total body weight,
including central volume of
distribution versus total body
weight (a), peripheral volume of
distribution versus total body
weight (b), oral bioavailability
versus total body weight (c), and
oral absorption rate versus total
body weight (d)
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clearance in morbidly obese patients which was based on
reports in in vitro and animal studies [4–7] and on oral
clearance of CYP3A substrates in studies in obese subjects
[13, 14]. Assuming that indeed the relative CYP3A activity
per unit of liver is reduced in morbidly obese patients [12],
we hypothesize that this effect may be counteracted by a
higher liver volume [34], resulting in a similar absolute
hepatic CYP3A metabolizing capacity in both groups. In
agreement with this hypothesis, Greenblatt et al. [15] also
found no significant difference in absolute CL of midazo-
lam between normal weight (66 ± 2 kg) and obese sub-
jects (117 ± 8 kg) (0.53 ± 0.04 vs. 0.47 ± 0.04 L/min,
respectively). However, for a study with triazolam, another
benzodiazepine CYP3A substrate, a lower apparent total
clearance of the drug from plasma after oral administra-
tion (CL/F) was found for obese patients [35]. Lower
CL/F values were also found for obese patients for the
CYP3A substrates taranabant and carbamazepine [36, 37].
Based on the results found in the current midazolam study
upon both oral and intravenous administration, it may be
hypothesized that these lower CL/F values [35–37] are due
to an increase in oral bioavailability instead of a decrease
in CL.
Oral bioavailability was found to be higher in morbidly
obese patients than in healthy volunteers [0.60 (13.2 %)
versus 0.28 (7.0 %)]. In contrast, Greenblatt et al. [15]
found similar values of oral midazolam bioavailability in
obese (0.42 ± 0.04) and normal weight patients
(0.40 ± 0.03) (P [ 0.05). This disagreement in results
may be explained by the higher body weights of the mor-
bidly obese subjects in our study versus the study of
Greenblatt et al. [15] (mean of 144 ± 22 vs. 117 ± 8 kg).
In addition, the concentration–time profiles after oral and
intravenous midazolam of a non-obese and an obese sub-
ject shown in their publication may also point at a higher
bioavailability in the obese patient. We anticipate that the
increase in oral bioavailability in morbidly obese patients
found in our study may be due to reduced CYP3A-
metabolizing activity in the intestines. Ulvestad et al. [12]
found in a study with 19 obese individuals [median BMI 45
(34–59) kg/m2] that CYP3A4 protein expression in the
small intestine and liver is lower with increasing BMI.
Another possible cause of increased bioavailability is an
increase in splanchnic blood flow, which has been reported
before in morbidly obese patients. An increase in villous
blood flow in the gut wall will cause an increase in
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residuals versus time of the final
model for 20 morbidly obese
patients (black dots) and 12
healthy volunteers (gray dots).
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substrate transport and thus carry the substrate away from
the intestinal CYP3A-metabolizing enzymes [38, 39].
Moreover, increased intestinal permeability may be
responsible for increased midazolam bioavailability as
obese patients showed increased paracellular absorption
measured with lactulose and chromium (Cr)-EDTA, which
may possibly be due to reduced tight junction function [40,
41]. A question would be whether the observed difference
in Ka between the morbidly obese patients and healthy
volunteers, which can be attributed to a difference in for-
mulation (tablet vs. oral solution), may have contributed to
the reported difference in oral bioavailability. In our
opinion, this difference in formulation is unlikely to
influence oral bioavailability, as midazolam is a highly
soluble and permeable drug that is expected to be 100 %
absorbed in the intestines [42]. Correspondingly, a study in
which six healthy volunteers received a midazolam 10 mg
oral solution, a 10 mg tablet, and a 5 mg intravenous bolus
dose showed similar oral bioavailability after both oral
dose formulations, 0.35 ± 0.07 versus 0.38 ± 0.12
(P [ 0.6), indicating no influence of oral formulation on
midazolam bioavailability [43].
To understand the net result of the influence of different
degrees of (morbid) obesity on each of the midazolam
pharmacokinetic parameters, simulations using the final
model were performed to yield midazolam concentration–
time profiles for subjects with different body weights. The
dose simulations show that the same intravenous bolus
dose to all subjects leads to lower initial concentrations in
morbidly obese patients due to a substantially higher cen-
tral and peripheral volume of distribution. This observed
increase in volume of distribution is in agreement with the
midazolam study of Greenblatt et al. [15] in which a sub-
stantial increase in total volume of distribution for obese
versus normal weight subjects of 311 ± 27 versus
114 ± 7 L (P \ 0.001) was also reported. Potentially,
these results can be explained by an increase in body
volume in terms of both well-perfused compartments
(organ and blood volume) and adipose tissue with obesity,
which is of specific relevance because midazolam is a
lipophilic drug [44, 45]. As such, directly after an intra-
venous bolus dose, lower midazolam concentrations and
associated effects may be expected in morbidly obese
patients. In addition, morbidly obese patients show an
increased t (Fig. 4), which can be attributed to the larger
volumes of distribution as well, as they allow for signifi-
cant midazolam disposition from the blood and may lead to
prolonged midazolam effects in morbidly obese patients
versus healthy volunteers. In contrast, a similar midazolam
oral dose will result in only slightly lower initial concen-
trations in morbidly obese patients versus healthy volun-
teers because the increased oral bioavailability counteracts
the influence of increased central volume of distribution on
midazolam Cmax values (Fig. 4). Finally, the increase in the
volumes of distribution with body weight also explains the
increased duration for morbidly obese patients to reach
steady-state concentrations after a continuous intravenous
infusion. This phenomenon has been described before for
diazepam in obese patients [46]. Therefore, a loading dose
or a higher initial continuous infusion rate may be con-
sidered to reach midazolam steady-state concentrations
more rapidly in morbidly obese patients.
There are some limitations to this study. Firstly, the
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Fig. 4 Population predicted midazolam concentrations over time in
three typical morbidly obese patients (112, 145, and 186 kg) and one
healthy volunteer (76 kg) after a 5 mg intravenous bolus dose
(logarithmic scale) (a), a 2.5 mg/h continuous infusion (linear scale)
(b), and a 7.5 mg oral dose (linear scale) (c)
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relatively short. Particularly in morbidly obese patients, the
midazolam Cmax values after the oral dose occurred at
approximately 90 min post-dose, leaving only a 60 min
time interval to collect data on the concentration decline
after the oral dose before the intravenous dose was
administered. However, in six of the 20 patients this
interval was [180 min (due to a delay in the surgery
schedule), thus providing significant information on the
midazolam pharmacokinetics after oral absorption in the
morbidly obese patients. Secondly, the healthy volunteer
group lacks a late sample post-intravenous dose, which
have may have an effect on the clearance and peripheral
volume of distribution estimates of the healthy volunteers
and thus obscure the covariate analysis. However, esti-
mated pharmacokinetic parameter values for this group
closely match those found in previous midazolam phar-
macokinetic studies in healthy volunteers, indicating ade-
quate precision of the pharmacokinetic parameters in
healthy volunteers and justifying the results from the
covariate analysis. Thirdly, morbidly obese patients
underwent surgery during the study, which may influence
midazolam clearance and distribution. However, we think
that surgery was only of minor influence as only the
intravenous dose was administered during surgery and CL
and volume of distribution found in this study were fairly
similar to earlier reported values in non-surgery obese
patients [15]. Finally, the stable isotope method for deter-
mining oral bioavailability in a single person on a single
occasion may have been preferable over the current semi-
simultaneous dosing design, though the semi-simultaneous
oral—intravenous administration method has proved a
reliable and accurate method for estimating oral bioavail-
ability and CL in a single person on a single occasion as
well [47–50]. Moreover, the available control data
(midazolam concentrations in healthy volunteers) was
gathered in a semi-simultaneous design. Lastly, the prep-
aration of the labeled drug and the determination of the
labeled drug in the samples is very expensive and labor
intensive. For these reasons, we have chosen to apply the
semi-simultaneous design.
5 Conclusion
This study shows that midazolam hepatic clearance was not
changed in morbidly obese patients versus healthy volun-
teers, while oral bioavailability was increased in morbidly
obese patients. Midazolam central and peripheral volumes
of distribution increased substantially with body weight,
resulting in lower midazolam concentrations after intra-
venous bolus administration and in an increased duration to
reach steady-state concentrations after midazolam contin-
uous infusion in morbidly obese patients in comparison
with healthy volunteers. Finally, initial midazolam con-
centrations after an oral dose were similar in morbidly
obese patients versus healthy volunteers. Further research
should elucidate the exact physiological changes at the
intestinal and hepatic level contributing to these findings.
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